Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial

José Luis Hernández MD, PhD, Francisco S Lozano MD, PhD, Vincent Riambau MD, PhD, Manuel Almendro-Delia MD, PhD, Juan Cosín-Sales MD, PhD, Sergi Bellmunt-Montoya MD, PhD, Javier Garcia-Alegria MD, PhD, Xavier Garcia-Moll MD, FESC, FACC, Juan José Gomez-Doblas MD, PhD, José R Gonzalez-Juanatey MD, PhD, Carmen Suarez Fernández MD

Article Type

Review

Published

In this narrative review, data about how to reduce residual risk through the best antithrombotic
approach among patients with peripheral artery disease, with a particular focus
on the COMPASS trial, are updated in order to provide some
practical recommendations about its use in this population.

Read more

Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin

Lale Tokgözoglu MD, José Luis Zamorano MD

Article Type

Meeting Report

Published

A meeting entitled ‘Current Perspective on the Use of Statins in the Treatment of Dyslipidemic Patients’ was held in Stresa, Italy, on 27–28th June 2019. This meeting report summarizes the main messages of the discussion with a special focus on pitavastatin, whose main features in different settings are described.

Read more

Nail enthesis ultrasound and automated software-guided assessment of bilateral common carotid intima–media thickness in psoriasis and psoriatic arthritis: is there a correlation with clinical and laboratory findings?

José Alexandre Mendonça PhD, Lucas Nogueira Pansani MD, Mateus Basso Mimoto MD, Igor Tadeu Garcia Ferreira MD, Fernanda Bertucci Sanches MD, Thais de Campos Ferreira Pinto MD, Vania Aparecida Leandro-Merhi PhD, José Luis Braga de Aquino PhD

Article Type

Original Research

Published

The objective of this study was to detect and correlate the changes that indicate the inflammatory and atherosclerotic process in psoriasis and psoriatic arthritis patients, using nail ultrasound and carotid artery intima–media thickness radiofrequency software.

Read more

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure

Edgardo Kaplinsky MD

Article Type

Review

Published

This review describes the results of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial and the recently published Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction (DEFINE-HF) trial. In addition, the thought-to-be mechanisms of action of SGLT2 inhibitors beyond their known glucose-lowering effects.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.